{
  "id": "dash_prediction_score",
  "title": "DASH Prediction Score for Recurrent VTE",
  "description": "Predicts likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Utilizes D-dimer, Age, Sex, and Hormonal therapy factors.",
  "category": "hematology",
  "version": "2012",
  "parameters": [
    {
      "name": "d_dimer_positive",
      "type": "string",
      "required": true,
      "description": "Post-anticoagulation D-dimer result (measured approximately 1 month after stopping anticoagulation)",
      "options": ["positive", "negative"],
      "validation": {
        "enum": ["positive", "negative"]
      }
    },
    {
      "name": "age",
      "type": "integer",
      "required": true,
      "description": "Patient age in years",
      "validation": {
        "min": 18,
        "max": 100
      },
      "unit": "years"
    },
    {
      "name": "sex",
      "type": "string",
      "required": true,
      "description": "Patient biological sex",
      "options": ["male", "female"],
      "validation": {
        "enum": ["male", "female"]
      }
    },
    {
      "name": "hormonal_therapy",
      "type": "string",
      "required": true,
      "description": "Hormonal therapy use at time of initial VTE (applies to women only, select 'not_applicable' for men)",
      "options": ["yes", "no", "not_applicable"],
      "validation": {
        "enum": ["yes", "no", "not_applicable"]
      }
    },
    {
      "name": "vte_type",
      "type": "string",
      "required": false,
      "description": "Type of initial venous thromboembolism for clinical context",
      "options": ["dvt_only", "pe_only", "dvt_and_pe", "not_specified"],
      "validation": {
        "enum": ["dvt_only", "pe_only", "dvt_and_pe", "not_specified"]
      }
    },
    {
      "name": "anticoagulation_duration",
      "type": "integer",
      "required": false,
      "description": "Duration of initial anticoagulation treatment in months",
      "validation": {
        "min": 3,
        "max": 24
      },
      "unit": "months"
    }
  ],
  "result": {
    "name": "dash_assessment",
    "type": "object",
    "unit": "points",
    "description": "DASH score with annual recurrence risk and anticoagulation recommendations"
  },
  "interpretation": {
    "ranges": [
      {
        "min": -2,
        "max": 1,
        "stage": "Low Risk",
        "description": "Low annual recurrence risk",
        "interpretation": "Annual VTE recurrence risk of 3.1% (95% CI 2.3-3.9%). Risk justifies stopping anticoagulation after 3-6 months of treatment. Consider discontinuing anticoagulation if bleeding risk is not elevated.",
        "annual_risk": "3.1%",
        "recommendation": "Consider discontinuing anticoagulation"
      },
      {
        "min": 2,
        "max": 2,
        "stage": "Intermediate Risk",
        "description": "Moderate annual recurrence risk",
        "interpretation": "Annual VTE recurrence risk of 6.4% (95% CI 4.8-7.9%). Moderate risk suggests need for individualized decision-making considering bleeding risk versus thrombosis risk.",
        "annual_risk": "6.4%",
        "recommendation": "Individualized decision based on bleeding risk"
      },
      {
        "min": 3,
        "max": 6,
        "stage": "High Risk",
        "description": "High annual recurrence risk",
        "interpretation": "Annual VTE recurrence risk of 12.3% (95% CI 9.9-14.7%). High risk warrants prolonged anticoagulation if bleeding risk is acceptable. Consider indefinite anticoagulation.",
        "annual_risk": "12.3%",
        "recommendation": "Consider prolonged/indefinite anticoagulation"
      }
    ]
  },
  "clinical_applications": [
    "Anticoagulation duration decision-making after first unprovoked VTE",
    "Risk stratification for VTE recurrence",
    "Patient counseling about recurrence risk",
    "Clinical trial enrollment and stratification",
    "Quality improvement initiatives in VTE management",
    "Healthcare resource allocation and monitoring",
    "Shared decision-making for anticoagulation therapy"
  ],
  "anticoagulation_guidance": {
    "low_risk": [
      "Consider discontinuing anticoagulation after 3-6 months",
      "Monitor for signs and symptoms of VTE recurrence",
      "Patient education about VTE risk factors and prevention",
      "Regular follow-up for risk reassessment",
      "Consider mechanical prophylaxis during high-risk periods"
    ],
    "intermediate_risk": [
      "Individualized decision-making required",
      "Assess bleeding risk using validated tools (HAS-BLED, HEMORR2HAGES)",
      "Consider patient preferences and quality of life factors",
      "Discuss risks and benefits of continued anticoagulation",
      "May consider extended anticoagulation (6-12 months) with reassessment"
    ],
    "high_risk": [
      "Strong consideration for prolonged anticoagulation",
      "Evaluate for indefinite anticoagulation if bleeding risk acceptable",
      "Regular monitoring for bleeding complications",
      "Periodic reassessment of risk-benefit ratio",
      "Consider newer anticoagulants with improved safety profiles"
    ]
  },
  "references": [
    "Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019-1025. doi: 10.1111/j.1538-7836.2012.04735.x.",
    "Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.",
    "Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738. doi: 10.1182/bloodadvances.2020001830.",
    "Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-1636. doi: 10.1161/CIRCULATIONAHA.109.925214."
  ],
  "formula": "DASH Score = (+2 if D-dimer positive) + (+1 if age ≤50 years) + (+1 if male) + (-2 if hormonal therapy in women)",
  "notes": [
    "Score applies only to patients with first unprovoked VTE",
    "D-dimer measured approximately 1 month after stopping anticoagulation",
    "Hormonal therapy scoring applies only to women (birth control, HRT)",
    "Excludes VTE during pregnancy, puerperium, trauma, surgery, immobilization, or active cancer",
    "Original validation used vitamin K antagonists",
    "External validation showed higher recurrence risk in patients >65 years even with low DASH scores",
    "Should be used in conjunction with bleeding risk assessment",
    "Tool aids in shared decision-making but does not replace clinical judgment",
    "Regular reassessment recommended as patient factors may change over time"
  ],
  "validation": {
    "population": "Patients with first unprovoked venous thromboembolism treated for ≥3 months",
    "settings": ["Hematology clinics", "Anticoagulation clinics", "Internal medicine", "Emergency departments"],
    "evidence_basis": "Derived from 1,818 cases with unprovoked VTE, externally validated",
    "clinical_utility": "Validated tool for VTE recurrence risk prediction and anticoagulation duration decisions"
  }
}